Article Sidebar
Views PDF: 2
RISK CATEGORY IN PROGNOSIS OF INVASIVE BREAST CARCINOMA
Main Article Content
Abstract
Objective: determine the St Gallen risk categories rate of female breast cancer patients, and association with survival outcome.
Patients and method: Retrospective data from Bach Mai and Ha Noi cancer hospitals comprised 300 women who were diagnosed with breast cancer between January 1st, 2017, and June 31st, 2019, and were followed up to June 31st, 2024 (cut off point for follow-up). Patients were stratified according to the St Gallen risk categories. To evaluate survival, Kaplan-Meier and Cox-regression model was conducted.
Results: The risk groups rates were LR – 12.3%, IR1 – 60.3%, IR2 – 7%, HR1 – 9%, HR2 – 11.3% , respectively. The distribution of five year survival outcome by risk categories as follow: the overall survival (OS) rates were LR – 100%, IR – 93.6%, HR – 78.7%, respectively; the DFS rates were LR – 100%, 93.1%, HR – 88.5%, respectively. OS and DFS curves were significantly different between the three risk categories (p < 0.05). IR1 and IR2 had a distinctly different OS ( p = 0.009) but it was independent of DFS (p = 0.114). HR1 and HR2 hav no difference in OS and DFS (pOS = 0.078, pDFS = 0.246).
Conclusion: St Gallen risk category was useful in predicting the prognosis breast cancer patients.
Article Details
Keywords
Breast cancer, risk category, survival
References
2. Li YH, Wang XY, Shen JW, et al. Clinical factors affecting the long-term survival of breast cancer patients. J Int Med Res. 2023; 51(3):03000605231164004. DOI:10.1177/03000605231164004.
3. Goldhirsch A, Wood WC, Gelber RD, et al. Progress and promise: Highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol. 2007; 18(7):1133-1144. DOI:10.1093/ annonc/mdm271.
4. Arriagada R, Le MG, Dunant A, Tubiana M, Contesso G. Twenty-five years of follow-up in patients with operable breast carcinoma: Correlation between clinicopathologic factors and the risk of death in each 5-year period. Cancer. 2006; 106(4):743-750. DOI:10.1002/cncr.21659.
5. Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer. 1989; 63(1):181-187. DOI:10.1002/1097-0142.
6. Weiss RB, Woolf SH, Demakos E, et al. Natural history of more than 20 years of node-positive primary breast carcinoma treated with cyclophosphamide, methotrexate, and fluorouracil-based adjuvant chemotherapy: A study by the Cancer and Leukemia Group B. J Clin Oncol. 2003; 21(9):1825-1835. DOI:10.1200/ JCO.2003.09.006.
7. D’Eredita’ G, Giardina C, Martellotta M, Natale T, Ferrarese F. Prognostic factors in breast cancer: The predictive value of the Nottingham Prognostic Index in patients with a long-term follow-up that were treated in a single institution. Eur J Cancer. 2001;37(5):591-596. DOI:10.1016/s0959- 8049(00)00435-4.
8. Iwamoto E, Fukutomi T, Akashi-Tanaka S. Validation and problems of St-Gallen recommendations of adjuvant therapy for node-negative invasive breast cancer in Japanese patients. Jpn J Clin Oncol. 2001; 31(6):259-262. DOI:10.1093/jjco/hye056.
9. Peiris H, Mudduwa L, Thalagala N, Jayatilake K. Validity of St Gallen risk categories in prognostication of breast cancer patients in Southern Sri Lanka. BMC Women’s Health. 2018; 18(1):30. DOI:10.1186/s12905-018-0524-1
10. Bauer K, Parise C, Caggiano V. Use of ER/PR/HER2 subtypes in conjunction with the 2007 St Gallen Consensus Statement for early breast cancer. BMC Cancer. 2010; 10:228. DOI:10.1186/1471-2407-10-228.